These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 26212540

  • 41. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway.
    Ho CH, Hsu JL, Liu SP, Hsu LC, Chang WL, Chao CC, Guh JH.
    Prostate; 2015 Sep; 75(13):1454-66. PubMed ID: 26180030
    [Abstract] [Full Text] [Related]

  • 42. MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
    Yang JS, Hour MJ, Huang WW, Lin KL, Kuo SC, Chung JG.
    J Pharmacol Exp Ther; 2010 Aug; 334(2):477-88. PubMed ID: 20463006
    [Abstract] [Full Text] [Related]

  • 43. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
    Whang YM, Park KH, Jung HY, Jo UH, Kim YH.
    Cancer; 2009 Mar 15; 115(6):1253-66. PubMed ID: 19156899
    [Abstract] [Full Text] [Related]

  • 44. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents.
    Ruan BF, Lu X, Li TT, Tang JF, Wei Y, Wang XL, Zheng SL, Yao RS, Zhu HL.
    Bioorg Med Chem; 2012 Jan 15; 20(2):1113-21. PubMed ID: 22189271
    [Abstract] [Full Text] [Related]

  • 45. Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.
    Zhang L, Qiang P, Yu J, Miao Y, Chen Z, Qu J, Zhao Q, Chen Z, Liu Y, Yao X, Liu B, Cui L, Jing H, Sun G.
    Autophagy; 2019 Mar 15; 15(3):391-406. PubMed ID: 30145925
    [Abstract] [Full Text] [Related]

  • 46. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
    Xia Y, Lei Q, Zhu Y, Ye T, Wang N, Li G, Shi X, Liu Y, Shao B, Yin T, Zhao L, Wu W, Song X, Xiong Y, Wei Y, Yu L.
    Cancer Lett; 2014 Dec 28; 355(2):297-309. PubMed ID: 25301449
    [Abstract] [Full Text] [Related]

  • 47. Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site.
    Li W, Sun H, Xu F, Shuai W, Liu J, Xu S, Yao H, Ma C, Zhu Z, Xu J.
    Bioorg Chem; 2019 Apr 28; 85():49-59. PubMed ID: 30599412
    [Abstract] [Full Text] [Related]

  • 48. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.
    Biochem Pharmacol; 2014 Aug 01; 90(3):320-30. PubMed ID: 24915421
    [Abstract] [Full Text] [Related]

  • 49. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N.
    Mol Cancer Ther; 2014 Dec 01; 13(12):2978-90. PubMed ID: 25313010
    [Abstract] [Full Text] [Related]

  • 50. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z, Gao M, Zhang H, Guan Q, Xu J, Li Y, Qi H, Li Z, Zuo D, Zhang W, Wu Y.
    Cancer Lett; 2017 Aug 28; 402():81-92. PubMed ID: 28576750
    [Abstract] [Full Text] [Related]

  • 51. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
    Tsai AC, Pai HC, Wang CY, Liou JP, Teng CM, Wang JC, Pan SL.
    Br J Pharmacol; 2014 Jan 28; 171(1):122-33. PubMed ID: 24116948
    [Abstract] [Full Text] [Related]

  • 52. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
    Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL.
    Cell Death Dis; 2014 Apr 10; 5(4):e1162. PubMed ID: 24722287
    [Abstract] [Full Text] [Related]

  • 53. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
    Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B, He Q.
    Cancer Lett; 2009 Nov 18; 285(1):13-22. PubMed ID: 19647933
    [Abstract] [Full Text] [Related]

  • 54. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity.
    Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z.
    J Pharmacol Exp Ther; 2015 Dec 18; 355(3):473-83. PubMed ID: 26377911
    [Abstract] [Full Text] [Related]

  • 55. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
    Cheng B, Zhu G, Meng L, Wu G, Chen Q, Ma S.
    Eur J Med Chem; 2022 Jan 15; 228():113930. PubMed ID: 34794817
    [Abstract] [Full Text] [Related]

  • 56. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
    Cao D, Liu Y, Yan W, Wang C, Bai P, Wang T, Tang M, Wang X, Yang Z, Ma B, Ma L, Lei L, Wang F, Xu B, Zhou Y, Yang T, Chen L.
    J Med Chem; 2016 Jun 23; 59(12):5721-39. PubMed ID: 27213819
    [Abstract] [Full Text] [Related]

  • 57. Induction of apoptosis through tubulin inhibition in human cancer cells by new chromene-based chalcones.
    Aryapour H, Riazi GH, Ahmadian S, Foroumadi A, Mahdavi M, Emami S.
    Pharm Biol; 2012 Dec 23; 50(12):1551-60. PubMed ID: 22984888
    [Abstract] [Full Text] [Related]

  • 58. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
    Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.
    Cancer Res; 2006 Jan 15; 66(2):951-9. PubMed ID: 16424030
    [Abstract] [Full Text] [Related]

  • 59. Mirabijalone E: a novel rotenoid from Mirabilis himalaica inhibited A549 cell growth in vitro and in vivo.
    Linghu L, Fan H, Hu Y, Zou Y, Yang P, Lan X, Liao Z, Chen M.
    J Ethnopharmacol; 2014 Aug 08; 155(1):326-33. PubMed ID: 24882730
    [Abstract] [Full Text] [Related]

  • 60. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest.
    Zuo D, Pang L, Shen J, Guan Q, Bai Z, Zhang H, Li Y, Lu G, Zhang W, Wu Y.
    Int J Oncol; 2017 Jun 08; 50(6):2069-2078. PubMed ID: 28440465
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.